CAS 117527-50-1

Paclitaxel succinate

Description:

Paclitaxel succinate is a derivative of the well-known chemotherapeutic agent paclitaxel, which is primarily used in the treatment of various cancers, including ovarian and breast cancer. This compound is characterized by the presence of a succinate moiety, which enhances its solubility and bioavailability compared to its parent compound. Paclitaxel succinate retains the core structure of paclitaxel, which includes a taxane ring system, and exhibits similar mechanisms of action, primarily through the stabilization of microtubules, thereby inhibiting cell division. The modification with succinate allows for improved pharmacokinetic properties, potentially leading to reduced side effects and enhanced therapeutic efficacy. Additionally, paclitaxel succinate can be formulated into various delivery systems, including nanoparticles and liposomes, to further optimize its delivery to tumor sites. Overall, this compound represents a significant advancement in the formulation of paclitaxel, aiming to improve cancer treatment outcomes while minimizing adverse effects.

Formula: C₅₁H₅₅NO₁₇

InChI: InChI=1S/C51H55NO17/c1-27-33(66-47(62)41(67-37(58)23-22-36(56)57)39(30-16-10-7-11-17-30)52-45(60)31-18-12-8-13-19-31)25-51(63)44(68-46(61)32-20-14-9-15-21-32)42-49(6,34(55)24-35-50(42,26-64-35)69-29(3)54)43(59)40(65-28(2)53)38(27)48(51,4)5/h7-21,33-35,39-42,44,55,63H,22-26H2,1-6H3,(H,52,60)(H,56,57)/t33-,34-,35+,39-,40+,41+,42-,44-,49+,50-,51+/m0/s1

InChI key: InChIKey=RBNOJYDPFALIQZ-LAVNIZMLSA-N

SMILES: O(C(C)=O)[C@]12[C@]3([C@H](OC(=O)C4=CC=CC=C4)[C@@]5(O)C(C)(C)C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@]1(OC2)[H])=C(C)[C@@H](OC([C@@H]([C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)OC(CCC(O)=O)=O)=O)C5)[H]

Synonyms:

• 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, butanedioic acid deriv.
• Butanedioic acid, mono[2-(benzoylamino)-1-[[[6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-phenylethyl] ester, [2aR-[2aα,4β,4aβ,6β,9α(1R*,2S*),11α,12α,12aα,12bα]]-
• Butanedioic acid, mono[(1R,2S)-2-(benzoylamino)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-phenylethyl] ester
• Butanedioic acid, 1-[(1R,2S)-2-(benzoylamino)-1-[[[(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl]oxy]carbonyl]-2-phenylethyl] ester
• 2′-Succinyltaxol
• Paclitaxel Succinate
• Paclitaxel-hemisuccinic acid
• Paclitaxel Impurity 59
• RBNOJYDPFALIQZ-LAVNIZMLSA-N

Paclitaxel-Succinic acid

CAS: 117527-50-1

Paclitaxel-Succinic acid, a derivative with a succinate linker, preps drug delivery conjugates for nanomedicine.

Formula: C₅₁H₅₅NO₁₇

Color and Shape: Solid

Molecular weight: 953.98

Ref: TM-T33862

Paclitaxel Succinate-d4

Controlled Product

CAS: 117527-50-1

Applications Paclitaxel Succinate-d4 is the labeled analogue of Paclitaxel Succinate (P132530), which ahs been used as a reactant for the preparation of molecular hydrogelators to be used as local delivery systems for chemotherapy.
References Wang, H., et. al.: J. Mater. Chem., 22, 16933 (2012)

Formula: C₅₁H₅₁D₄NO₁₇

Color and Shape: Neat

Molecular weight: 958.0

Ref: TR-P132532

Paclitaxel Succinate

Controlled Product

CAS: 117527-50-1

Applications Paclitaxel Succinate has been used as a reactant for the preparation of molecular hydrogelators to be used as local delivery systems for chemotherapy.
References Wang, H., et. al.: J. Mater. Chem., 22, 16933 (2012)

Formula: C₅₁H₅₅NO₁₇

Color and Shape: Neat

Molecular weight: 953.98

Ref: TR-P132530

Paclitaxel Succinate

CAS: 117527-50-1

Formula: C₅₁H₅₅NO₁₇

Molecular weight: 953.99

Ref: ST-EA-CP-P36004